Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04352777
Recruitment Status : Recruiting
First Posted : April 20, 2020
Last Update Posted : September 23, 2020
Sponsor:
Information provided by (Responsible Party):
Duke University

Brief Summary:
The purpose of this study is to perform an in depth analysis of changes in the tumor immune microenvironment in patients undergoing treatment with standard of care endocrine therapy and abemaciclib in the advanced setting via singe cell RNA sequencing. The investigators will also correlate changes in serum estrogen levels to changes in tumor and peripheral immune cell repertoire and function (including regulatory T cell populations, B cells, myeloid-derived suppressor cell populations, T cell activation and T cell exhaustion).This study has two cohorts with 15 patients in each cohort.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Locally Advanced Breast Cancer Hormone Receptor Positive Tumor Drug: Abemaciclib Drug: Fulvestrant Drug: Aromatase Inhibitors Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Effects of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Actual Study Start Date : September 14, 2020
Estimated Primary Completion Date : August 17, 2022
Estimated Study Completion Date : August 17, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Active Comparator: Cohort 1
Fulvestrant plus abemaciclib
Drug: Abemaciclib
50 - 150mg tablet BID as prescribed per standard of care

Drug: Fulvestrant
500mg as prescribed per standard of care

Active Comparator: Cohort 2
Aromatase inhibitor plus abemaciclib (with or without ovarian suppression)
Drug: Abemaciclib
50 - 150mg tablet BID as prescribed per standard of care

Drug: Aromatase Inhibitors
Letrozole, anastrozole as prescribed per standard of care




Primary Outcome Measures :
  1. Changes in serum estrogen (E1 and E2) levels compared to changes in tumor immune cell repertoire and function in response to endocrine therapy and CDK 4/6 inhibition [ Time Frame: Through study completion, approximately 2 years ]
    Estrogen levels in the blood will be assessed to correlate with changes in immune cell populations within the tumor.

  2. Changes in serum estrogen (E1 and E2) levels compared to peripheral blood mononuclear cell repertoire and function in response to endocrine therapy and CDK 4/6 inhibition [ Time Frame: Through study completion, approximately 2 years ]
    Estrogen levels in the blood will be assessed to correlate with changes in the characterization and functionality of peripheral blood mononuclear cells including regulatory T cell populations, B cells, myeloid-derived suppressor cell populations, T cell activation and T cell exhaustion.


Secondary Outcome Measures :
  1. Changes in tumor immune cell populations in response to fulvestrant and aromatase inhibitor therapy plus abemaciclib, measured by sequential biopsies [ Time Frame: Baseline, 4 weeks ]
    Changes in tumor immune cell populations will be assessed by sequential biopsies via single cell RNA sequencing analysis of fresh tissue

  2. Differences in tumor immune cell infiltrate and peripheral blood mononuclear cells in response to fulvestrant versus aromatase inhibition plus CDK4/6 inhibition, measured by sequential biopsies and blood collection [ Time Frame: Baseline, 4 weeks ]
    Tumor immune cell and peripheral blood monoclonal cell changes assessed by sequential biopsies via single cell RNA sequencing analysis of fresh tissue

  3. To correlate unique immune cell populations identified with progression free survival in the overall population [ Time Frame: Through study completion, approximately 2 years ]
    Unique immune cell populations will be identified via single cell RNA sequencing and correlated to progression free survival measured by RECIST1.1.

  4. Best overall response rate of abemaciclib and endocrine therapy in both treatment arms [ Time Frame: Through study completion, approximately 2 years ]
    Best overall response rate to both treatment arms measured by RECIST 1.1

  5. Progression free survival in response to abemaciclib and endocrine therapy in both treatment arms [ Time Frame: Through study completion, approximately 2 years ]
    Progression free survival rate to both treatment arms measured by RECIST 1.1

  6. Number of participants with at least one serious adverse event [ Time Frame: Through study completion, approximately 2 years ]
    Serious adverse events will include only those related to abemaciclib, endocrine therapy, and/or study-related biopsies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women age ≥ 18
  2. Locally advanced/unresectable or metastatic breast cancer
  3. Histologically documented estrogen receptor positive adenocarcinoma of the breast that is (any progesterone status allowed):

    • ER positive defined as ≥ 10 % tumor cells positive for ER by immunohistochemistry (IHC), irrespective of staining intensity.
    • HER2 negative status is determined by:
    • IHC 1+, as defined by incomplete membrane staining that is faint/barely perceptible and within > 10% of invasive tumor cells, or
    • IHC 0, as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within ≤ 10% of the invasive tumor cells, or
    • FISH negative based on:
    • Single-probe average HER2 copy number < 4.0 signals / cell, or
    • Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number < 4.0 signals /cell
  4. Patients should have plans to initiate standard of care endocrine therapy with non-steroidal aromatase inhibitor (letrozole, anastrazole) OR fulvestrant plus abemaciclib in the advanced/metastatic first-line or second-line setting per treating oncologist discretion
  5. Patients should be willing and able to undergo fresh biopsy pretreatment and at 4 weeks into treatment.
  6. Patients should have an accessible lesion representative of recurrent or metastatic breast cancer for biopsy. Patients will undergo a tissue biopsy or tissue collection for research purposes only. Sites for tissue acquisition include the breast, skin/chest wall, soft tissue, liver, bone. Research directed lung biopsies and brain biopsies are not permitted. Procedures for tissue acquisition are restricted to those performed under local anesthesia or IV conscious sedation; biopsies that require general anesthesia are not permitted in this situation.
  7. Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy).
  8. Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy.
  9. The patient is able to swallow oral medications.
  10. The patient has adequate organ function for all of the following criteria, as defined in below.

    • Hematologic
    • ANC ≥1.5 × 10^9/L
    • Platelets ≥100 × 10^9/L
    • Hemoglobin ≥ 8 g/dL. * Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.
    • Hepatic
    • Total bilirubin ≤1.5 × ULN *Patients with Gilbert's syndrome with a total bilirubin ≤ 2.0 times ULN and direct bilirubin within normal limits are permitted.
    • ALT and AST ≤ 3 × ULN

      • Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; ULN = upper limit of normal.
  11. Able and willing to complete the informed consent process
  12. Agree to have bio-specimens stored for future research

Exclusion Criteria:

  1. History of concurrent active malignancy within last 5 years (excluding basal cell skin cancer, resected squamous cell carcinoma of the skin)
  2. Current use of hormonal birth control (copper IUD allowed) or estrogen replacement therapy
  3. Active autoimmune disease that has required systemic treatment in past 6 months (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or similar treatment) is not considered a form of systemic treatment.
  4. History of a serious or life-threatening allergic reaction to local anesthetics (e.g., lidocaine, xylocaine) used during a biopsy procedure
  5. Immunodeficient subjects, E.G., receiving systemic steroid therapy greater than physiologic doses or any other form of immunosuppressive therapy within 30 days prior to the first dose of endocrine therapy treatment
  6. Concurrent use of other oncologic therapies in the adjuvant setting other than bisphosphonates
  7. Patients with disease not amenable to biopsy
  8. The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  9. Females who are pregnant or lactating.
  10. The patient has active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.
  11. The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
  12. History of bleeding disorder that would make serial biopsies unsafe.
  13. Patients of active anticoagulation for history of venous thromboembolism, cardiovascular conditions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04352777


Contacts
Layout table for location contacts
Contact: Kate Hogan, MS 919-660-1278 katherine.hogan@duke.edu

Locations
Layout table for location information
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Duke Breast Oncology Research    919-660-1278      
Principal Investigator: Sarah Sammons, MD         
Sponsors and Collaborators
Duke University
Investigators
Layout table for investigator information
Principal Investigator: Sarah Sammons, MD Duke University
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT04352777    
Other Study ID Numbers: Pro00103625
First Posted: April 20, 2020    Key Record Dates
Last Update Posted: September 23, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Duke University:
metastatic breast cancer
abemaciclib
endocrine therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Fulvestrant
Aromatase Inhibitors
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action